Summary & Overview
CPT 81529: mRNA Expression Profiling for Melanoma Recurrence Risk
CPT code 81529 represents a laboratory-developed molecular diagnostic assay that quantifies mRNA expression of 31 genes from FFPE melanoma tumor tissue and applies an algorithm to report a risk score for recurrence and the likelihood of sentinel lymph node metastasis. This code matters nationally because it supports clinical decision-making about surveillance and surgical management for cutaneous melanoma by providing prognostic information beyond traditional histopathology. Payers commonly reviewing coverage for this test include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find benchmarks and guidance on the clinical context for use of this assay, an overview of payer coverage considerations, and the operational implications for laboratories and ordering clinicians. The content summarizes what the code represents, typical sites of service, and the clinical purpose—risk stratification for melanoma recurrence and sentinel node metastasis probability. Where available, the publication will cover reimbursement benchmarks, coding and billing considerations, and relevant policy trends that may affect access to molecular prognostic testing for cutaneous melanoma. Data not available in the input is noted as such in specific sections.
Billing Code Overview
CPT code 81529 describes a laboratory diagnostic assay performed on a formalin–fixed paraffin–embedded (FFPE) tumor tissue specimen to measure mRNA expression of 31 genes (28 content genes and 3 housekeeping genes). The test includes both the technical laboratory analysis of the FFPE specimen and an algorithmic computation that combines test results with patient data to generate a risk score for cutaneous melanoma recurrence, including the likelihood of sentinel lymph node metastasis.
-
Service type: Laboratory molecular diagnostic test with algorithmic risk modeling
-
Typical site of service: Clinical molecular diagnostics laboratory (specimen collected at outpatient or hospital setting; testing performed in a reference or hospital lab)
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents with a newly diagnosed cutaneous melanoma after wide local excision of a suspicious pigmented lesion. The surgical pathology report on formalin–fixed paraffin–embedded (FFPE) tumor tissue confirms invasive melanoma and requests prognostic molecular testing to refine recurrence risk and sentinel lymph node involvement probability. The specimen block is sent to an external clinical molecular laboratory. A histology technician prepares unstained FFPE sections; a molecular technologist performs mRNA extraction and a validated 31-gene expression assay. A laboratory analyst carries out the technical assay and runs the algorithmic analysis incorporating the assay results and available clinicopathologic data to generate a continuous and categorical risk score for melanoma recurrence and estimated likelihood of sentinel lymph node metastasis. Results are reported to the ordering dermatologist, surgical oncologist or medical oncologist and become part of the medical record to inform surveillance intensity and consideration of staging or adjuvant therapy. Typical sites of service include hospital-based pathology laboratories, independent clinical molecular laboratories, and outpatient reference laboratories that receive FFPE surgical pathology specimens.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Append when reporting only the professional (interpretive) component if applicable for split billing; for lab-only molecular tests this is rarely used but applies when a pathologist provides separate interpretation. |